Organisation/Company: Università degli studi di Messina Research Field: Medical sciences, Biological sciences, Pharmacological sciences Researcher Profile: Recognised Researcher (R2), Leading Researcher (R4), First Stage Researcher (R1), Established Researcher (R3) Country: Italy Application Deadline: 14 Jan 2025 - 12:00 (UTC) Type of Contract: To be defined Job Status: Not Applicable Is the job funded through the EU Research Framework Programme? Not funded by a EU programme Is the Job related to staff position within a Research Infrastructure? No Offer Description The project focuses on the issue of the immunogenicity associated with RNA therapeutics, one of the main obstacles to their development. The project aims to identify the key immune sensors involved in the reactogenicity of RNA drugs, analyzing how these sensors interact with prototype RNA therapy molecules of different immunogenicity. Using a large panel of genetically modified mice, lacking key molecules of the innate immune system, the immunological mechanisms underlying the responses to these drugs will be studied. The project includes a series of activities exploring the role of specific immune receptors and sensors, such as MAVS, ZBP1, Myd88, RI, SING, and NRP3, in mediating the immune response to RNA drugs. The final goal is to improve the safety and efficacy of RNA therapeutics. Minimum Requirements Master's/specialist/old system degree relating to the relevant scientific disciplinary area obtained in Italy or the equivalent qualification obtained abroad. Degree Course in Medicine and Surgery (LM41) Degree Course in Medical, Veterinary and Pharmaceutical Biotechnology (LM9) Bachelor's Degree in Chemical, Biological, Pharmaceutical and Environmental Sciences (LM6) DOCTORATE on subjects related to the topics of the research grant Eligibility of fellows: country/ies of residence: EUROPE Eligibility of fellows: nationality/ies: EUROPE Selection Process RNA-based therapeutics; Molecular mechanisms of innate immunity and nucleic acid sensing; Immune sensors in adverse drug reactions in RNA-based therapeutics. J-18808-Ljbffr